Drug Approval | May 14, 2025
Briefs: Zydus and CuraTeQ Biologics
CuraTeQ Biologics receives approval for biosimilar Zefylti from UK’s MHRA
CuraTeQ Biologics receives approval for biosimilar Zefylti from UK’s MHRA
he inspection covering the sterile drug product filling and packaging line, quality systems and quality control laboratories concluded compliance with the principles and guidelines of Good Manufacturing Practice
The portfolio consists of liquids and immediate release solid orals which are in the therapeutic segment to treat infections associated with UTIs
Celecoxib Capsules approval complements Strides’ existing products to serve a broader patient base
Trastuzumab specifically binds and inhibits the human epidermal growth factor receptor 2 (HER2) protein
Bayer expects 2025 to be the most difficult year of its turnaround
Syngene reported revenue growth of 11% year-on-year, and 8% sequentially crossing the Rs. 1,000 Cr in a quarter threshold for the first time
Access to NIPT, TB and Rare Disease diagnostics to benefit thousands of patients nationwide
Mistry is a seasoned finance professional having an extensive work experience spanning more than 25 years
The company does not expect this development to have any material impact on the current business operations
Subscribe To Our Newsletter & Stay Updated
